{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-195400","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.296853+00:00","generated_at":"2026-05-31T11:37:18.435857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Madrigal reports Q2 2024 net sales of $14.6M from Rezdiffra launch; cash $1.1B","bullets":["Rezdiffra U.S. launch generated $14.6M net sales in Q2 2024; no product sales in prior-year period.","Coverage in place for >50% of commercial lives; <5% of covered lives require biopsy.","EMA decision on resmetirom MAA expected mid-2025; plans to directly commercialize in Europe.","Q2 operating expenses $177.2M vs $86.5M YoY; SG&A drove increase on launch activities.","Cash, equivalents and marketable securities $1.1B vs $634.1M at Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-195400","json":"https://secwatch.observer/filing/0001193125-24-195400.json","markdown":"https://secwatch.observer/filing/0001193125-24-195400.md","text":"https://secwatch.observer/filing/0001193125-24-195400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524195400/0001193125-24-195400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524195400/d813823d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:37:18.435857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}